Align Technology, Inc. (ALGN)
NASDAQ: ALGN · Real-Time Price · USD
171.41
+4.23 (2.53%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Align Technology Market Cap
Align Technology has a market cap or net worth of $12.55 billion as of April 17, 2025. Its market cap has decreased by -46.12% in one year.
Market Cap
12.55B
Enterprise Value
11.62B
1-Year Change
-46.12%
Ranking
Category
Stock Price
$171.41
Market Cap Chart
Since January 30, 2001, Align Technology's market cap has increased from $769.80M to $12.55B, an increase of 1,530.16%. That is a compound annual growth rate of 12.21%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Apr 17, 2025 | 12.62B | -18.95% |
Dec 31, 2024 | 15.57B | -25.83% |
Dec 29, 2023 | 20.99B | 27.39% |
Dec 30, 2022 | 16.47B | -68.21% |
Dec 31, 2021 | 51.82B | 22.98% |
Dec 31, 2020 | 42.14B | 91.60% |
Dec 31, 2019 | 21.99B | 31.29% |
Dec 31, 2018 | 16.75B | -5.97% |
Dec 29, 2017 | 17.81B | 132.55% |
Dec 30, 2016 | 7.66B | 46.35% |
Dec 31, 2015 | 5.23B | 16.61% |
Dec 31, 2014 | 4.49B | -2.19% |
Dec 31, 2013 | 4.59B | 103.21% |
Dec 31, 2012 | 2.26B | 21.17% |
Dec 30, 2011 | 1.86B | 25.00% |
Dec 31, 2010 | 1.49B | 12.37% |
Dec 31, 2009 | 1.33B | 126.20% |
Dec 31, 2008 | 586.60M | -48.68% |
Dec 31, 2007 | 1.14B | 27.70% |
Dec 29, 2006 | 895.10M | 122.94% |
Dec 30, 2005 | 401.50M | -38.40% |
Dec 31, 2004 | 651.80M | -32.58% |
Dec 31, 2003 | 966.80M | 628.01% |
Dec 31, 2002 | 132.80M | -38.40% |
Dec 31, 2001 | 215.60M | -71.99% |
View and export this data all the way back to 2001.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Eli Lilly and Company | 659.93B |
UnitedHealth Group | 535.14B |
Johnson & Johnson | 370.90B |
AbbVie | 303.70B |
Novo Nordisk | 284.50B |
Abbott Laboratories | 224.94B |
AstraZeneca | 210.38B |
Novartis AG | 210.23B |